2-((2-(diethylamino)ethyl)thio)acetic acid | 155160-95-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-((2-(diethylamino)ethyl)thio)acetic acid
• 英文别名: 2-[2-(Diethylazaniumyl)ethylsulfanyl]acetate
• CAS: 155160-95-5
• 化学式: C₈H₁₇NO₂S
• 分子量: 191.294
• InChiKey: RDRAHLHBWBXXLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  69.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-((2-(diethylamino)ethyl)thio)acetic acid 、 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以76%的产率得到
  参考文献：
  名称：

  ANTIMICROBIAL AND ANTITUBERCULAR COMPOUNDS

  摘要：

  由结核分枝杆菌引起的感染每年导致超过180万人死亡。尽管这种病原菌种的持续存在和多药耐药菌株的出现已经产生了对新结核病疗法的迫切需求，但40多年来，还没有开发出一种针对结核病的新特异性药物。本披露提供了小型分子的简短且可扩展的合成方法，以及作为消除这种威胁生命病原体的新疗法的小分子。

  公开号：

  US20120010281A1

文献信息

• [EN] IONIZABLE CATIONIC LIPID FOR RNA DELIVERY<br/>[FR] LIPIDE CATIONIQUE IONISABLE POUR ADMINISTRATION D'ARN
  申请人：ARCTURUS THERAPEUTICS INC

  公开号：WO2015074085A1

  公开（公告）日：2015-05-21

  What is described is a compound of formula (I), wherein R1 and R2 are the same or different, each a linear or branched alkyl with 1-9 carbons, or an alkenyl or alkynyl with 2 to 11 carbon atoms; L1 and L2 are the same or different, each a linear alkyl having 5 to 18 carbon atoms, or form a heterocycle with N; X1 is a bond, or is -CO-O- whereby L2-CO-O-R2 is formed; X2 is S or O; L3 is a bond or a lower alkyl, or form a heterocycle with N; R3 is a lower alkyl; and R4 and R5 are the same or different, each a lower alkyl; or a pharmaceutically acceptable salt thereof.

  所描述的是一种具有化学式（I）的化合物，其中R1和R2相同或不同，各自是具有1-9个碳原子的直链或支链烷基，或具有2-11个碳原子的烯烃或炔烃；L1和L2相同或不同，各自是具有5-18个碳原子的直链烷基，或与N形成杂环；X1是键，或是-CO-O-，从而形成L2-CO-O-R2；X2是S或O；L3是键或低烷基，或与N形成杂环；R3是低烷基；R4和R5相同或不同，各自是低烷基；或其药用可接受的盐。
• IONIZABLE CATIONIC LIPID FOR RNA DELIVERY
  申请人：Arcturus Therapeutics, Inc.

  公开号：US20150141678A1

  公开（公告）日：2015-05-21

  What is described is a compound of formula (1) wherein R 1 and R 2 are the same or different, each a linear or branched alkyl with 1-9 carbons, or an alkenyl or alkynyl with 2 to 11 carbon atoms; L 1 and L 2 are the same or different, each a linear alkyl having 5 to 18 carbon atoms, or form a heterocycle with N; X 1 is a bond, or is —CO—O— whereby L 2 -CO—O—R 2 is formed; X 2 is S or O; L 3 is a bond or a lower alkyl, or form a heterocycle with N; R 3 is a lower alkyl; and R 4 and R 5 are the same or different, each a lower alkyl; or a pharmaceutically acceptable salt thereof.

  所描述的化合物为公式（1）的化合物，其中R1和R2相同或不同，均为具有1-9个碳原子的线性或支链烷基，或具有2到11个碳原子的烯基或炔基；L1和L2相同或不同，均为具有5到18个碳原子的线性烷基，或与N形成杂环；X1为键或为—CO—O—，从而形成L2-CO—O—R2；X2为S或O；L3为键或较低烷基，或与N形成杂环；R3为较低烷基；R4和R5相同或不同，均为较低烷基；或其药学上可接受的盐。
• SYMMETRIC IONIZABLE CATIONIC LIPID FOR RNA DELIVERY
  申请人：Arcturus Therapeutics, Inc.

  公开号：US20150239834A1

  公开（公告）日：2015-08-27

  What are described are compounds of formulas II, III, and IV. The compound of formula II consists of a compound in which R 1 and R 2 are both a linear alkyl consisting of 1 to 12 carbons, an alkenyl or alkynyl consisting of 2 to 12 carbons; L 1 and L 2 both consist of a linear alkylene or alkenylene consisting of 5 to 18 carbons, or forming a heterocycle with N; X is S; L 3 consists of a bond or a linear alkylene consisting of 1 to 6 carbons, or forming a heterocycle with N; R 3 consists of a linear or branched alkylene consisting of 1 to 6 carbons; and R 4 and R 5 are the same or different, each consisting of hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons. The compound of formulas III and IV consists of a compound in which R 1 consists of a branched alkyl with 12 to 20 carbons; R 2 consists of a linear alkyl with 5 to 10 carbons or a branched alkyl with 12 to 20 carbons; L 1 and L 2 each consists of a bond or a linear alkyl having 1 to 3 carbon atoms; X consists of S or O; L 3 consists of a bond or a lower alkyl; R 3 consists of a lower alkyl; and R 4 and R 5 are the same or different, each consisting of a lower alkyl. The compound of formulas II, III and IV may comprise a pharmaceutically acceptable salt thereof.

  所描述的是II、III和IV式化合物。式I的化合物由化合物组成，其中R1和R2都是由1到12个碳组成的直链烷基、由2到12个碳组成的烯基或炔基；L1和L2都由由5到18个碳组成的直链烷基或烯基组成，或与N形成杂环；X为S；L3由键或由1到6个碳组成的直链烷基组成，或与N形成杂环；R3由由1到6个碳组成的直链或支链烷基组成；R4和R5相同或不同，分别由氢或由1到6个碳组成的直链或支链烷基组成。式III和IV的化合物由化合物组成，其中R1由由12到20个碳组成的支链烷基组成；R2由由5到10个碳组成的直链烷基或由12到20个碳组成的支链烷基组成；L1和L2分别由键或由1到3个碳组成的直链烷基组成；X为S或O；L3由键或由低碳的烷基组成；R3由低碳的烷基组成；R4和R5相同或不同，分别由低碳的烷基组成。II、III和IV式化合物可以包括其药学上可接受的盐。
• Lankacidin derivatives and production thereof
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0226896A2

  公开（公告）日：1987-07-01

  The present invention provides lankacidin derivative [1] and production thereof. The lankacidin derivative [1] shows excellent anti- microbial activities and thus can be used for prophylaxis and treatment of infectious disease in animals.

  本发明提供了兰卡苷衍生物[1]及其生产方法。 兰卡苷衍生物[1]具有优异的抗微生物活性，因此可用于动物传染病的预防和治疗。
• Ionizable cationic lipid for RNA delivery
  申请人：Arcturus Therapeutics, Inc.

  公开号：US10399937B2

  公开（公告）日：2019-09-03

  What is described herein are cationic lipids that facilitate the intracellular delivery of biologically active molecules, comprising a compound of formula I wherein R1 is a linear alkyl, alkenyl, or alkynyl of 2 to 12 carbons, or a branched alkyl with 7-25 R2 is a branched alkenyl with 7-25 carbons, L1 and L2 are independently a linear alkenylene with 2-18 carbons, X is S or O, L3 is a bond, and R3 R4, and R5 are each a linear or branched alkylene with 1-6 carbons.

  本文所述的阳离子脂质可促进生物活性分子在细胞内的传递，由式 I 的化合物组成 其中 R1 是碳原子数为 2-12 的直链烷基、烯基或炔基，或碳原子数为 7-25 的支链烷基；R2 是碳原子数为 7-25 的支链烯基；L1 和 L2 独立地是碳原子数为 2-18 的直链烯基；X 是 S 或 O；L3 是键；R3、R4 和 R5 分别是碳原子数为 1-6 的直链或支链烯基。